Gastric cancer‐survival at the pennsylvania hospital with and without adjuvant chemotherapy

H. Lerner, E. Marcovitz, Howard A. Zaren

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

From 1964 to 1974, 122 patients were treated for gastric cancer; none of these patients received chemotherapy; 13 of this group were lost to follow‐up. In 34 patients, the disease was too far advanced for surgical resection. Their survival ranged from 0.1 month to 7.5 months with a median survival of 1.1 months. Seventy‐four patients were resected for cure; 60 patients underwent a subtotal gastrectomy. Survival ranged from 0 to 72 months with a median of eight months. Fourteen patients had total gastrectomies; survival ranged from 0.1 to 72 months with a median of 5.5 months. Only six of the resected patients had negative lymph nodes; their survival ranged from four to 36 months. In this series there were 11 operative deaths and only seven patients survived five years. Thirty‐one patients who had resections were treated with adjuvant chemotherapy consisting of 0.5 g 5‐fluorouracil.(5‐FU) IV on days 1, 8, 15, etc, and hydroxyurea (HU), 80 mg/kg per os (p.o.), on days 4, 11, 18, etc. This group has a range of survival from three to 164 months and a median survival of 25 months. Fifteen consecutive patients with nonresectable gastric cancer were treated with HU‐FU with a survival of one to 30 months and a median survival of eight months. In patients with measurable disease, objective regression was clearly demonstrated.

Original languageEnglish (US)
Pages (from-to)201-204
Number of pages4
JournalJournal of Surgical Oncology
Volume23
Issue number3
DOIs
StatePublished - Jan 1 1983

Fingerprint

Adjuvant Chemotherapy
Stomach
Survival
Gastrectomy
Stomach Neoplasms
Hydroxyurea
Fluorouracil
Lymph Nodes
Drug Therapy

Keywords

  • gastric cancer
  • survival
  • with and without adjuvant chemotherapy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Gastric cancer‐survival at the pennsylvania hospital with and without adjuvant chemotherapy. / Lerner, H.; Marcovitz, E.; Zaren, Howard A.

In: Journal of Surgical Oncology, Vol. 23, No. 3, 01.01.1983, p. 201-204.

Research output: Contribution to journalArticle

Lerner, H. ; Marcovitz, E. ; Zaren, Howard A. / Gastric cancer‐survival at the pennsylvania hospital with and without adjuvant chemotherapy. In: Journal of Surgical Oncology. 1983 ; Vol. 23, No. 3. pp. 201-204.
@article{d49c250a649049b5a1bbb6855c1d0d70,
title = "Gastric cancer‐survival at the pennsylvania hospital with and without adjuvant chemotherapy",
abstract = "From 1964 to 1974, 122 patients were treated for gastric cancer; none of these patients received chemotherapy; 13 of this group were lost to follow‐up. In 34 patients, the disease was too far advanced for surgical resection. Their survival ranged from 0.1 month to 7.5 months with a median survival of 1.1 months. Seventy‐four patients were resected for cure; 60 patients underwent a subtotal gastrectomy. Survival ranged from 0 to 72 months with a median of eight months. Fourteen patients had total gastrectomies; survival ranged from 0.1 to 72 months with a median of 5.5 months. Only six of the resected patients had negative lymph nodes; their survival ranged from four to 36 months. In this series there were 11 operative deaths and only seven patients survived five years. Thirty‐one patients who had resections were treated with adjuvant chemotherapy consisting of 0.5 g 5‐fluorouracil.(5‐FU) IV on days 1, 8, 15, etc, and hydroxyurea (HU), 80 mg/kg per os (p.o.), on days 4, 11, 18, etc. This group has a range of survival from three to 164 months and a median survival of 25 months. Fifteen consecutive patients with nonresectable gastric cancer were treated with HU‐FU with a survival of one to 30 months and a median survival of eight months. In patients with measurable disease, objective regression was clearly demonstrated.",
keywords = "gastric cancer, survival, with and without adjuvant chemotherapy",
author = "H. Lerner and E. Marcovitz and Zaren, {Howard A.}",
year = "1983",
month = "1",
day = "1",
doi = "10.1002/jso.2930230317",
language = "English (US)",
volume = "23",
pages = "201--204",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Gastric cancer‐survival at the pennsylvania hospital with and without adjuvant chemotherapy

AU - Lerner, H.

AU - Marcovitz, E.

AU - Zaren, Howard A.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - From 1964 to 1974, 122 patients were treated for gastric cancer; none of these patients received chemotherapy; 13 of this group were lost to follow‐up. In 34 patients, the disease was too far advanced for surgical resection. Their survival ranged from 0.1 month to 7.5 months with a median survival of 1.1 months. Seventy‐four patients were resected for cure; 60 patients underwent a subtotal gastrectomy. Survival ranged from 0 to 72 months with a median of eight months. Fourteen patients had total gastrectomies; survival ranged from 0.1 to 72 months with a median of 5.5 months. Only six of the resected patients had negative lymph nodes; their survival ranged from four to 36 months. In this series there were 11 operative deaths and only seven patients survived five years. Thirty‐one patients who had resections were treated with adjuvant chemotherapy consisting of 0.5 g 5‐fluorouracil.(5‐FU) IV on days 1, 8, 15, etc, and hydroxyurea (HU), 80 mg/kg per os (p.o.), on days 4, 11, 18, etc. This group has a range of survival from three to 164 months and a median survival of 25 months. Fifteen consecutive patients with nonresectable gastric cancer were treated with HU‐FU with a survival of one to 30 months and a median survival of eight months. In patients with measurable disease, objective regression was clearly demonstrated.

AB - From 1964 to 1974, 122 patients were treated for gastric cancer; none of these patients received chemotherapy; 13 of this group were lost to follow‐up. In 34 patients, the disease was too far advanced for surgical resection. Their survival ranged from 0.1 month to 7.5 months with a median survival of 1.1 months. Seventy‐four patients were resected for cure; 60 patients underwent a subtotal gastrectomy. Survival ranged from 0 to 72 months with a median of eight months. Fourteen patients had total gastrectomies; survival ranged from 0.1 to 72 months with a median of 5.5 months. Only six of the resected patients had negative lymph nodes; their survival ranged from four to 36 months. In this series there were 11 operative deaths and only seven patients survived five years. Thirty‐one patients who had resections were treated with adjuvant chemotherapy consisting of 0.5 g 5‐fluorouracil.(5‐FU) IV on days 1, 8, 15, etc, and hydroxyurea (HU), 80 mg/kg per os (p.o.), on days 4, 11, 18, etc. This group has a range of survival from three to 164 months and a median survival of 25 months. Fifteen consecutive patients with nonresectable gastric cancer were treated with HU‐FU with a survival of one to 30 months and a median survival of eight months. In patients with measurable disease, objective regression was clearly demonstrated.

KW - gastric cancer

KW - survival

KW - with and without adjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0020624104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020624104&partnerID=8YFLogxK

U2 - 10.1002/jso.2930230317

DO - 10.1002/jso.2930230317

M3 - Article

C2 - 6865441

AN - SCOPUS:0020624104

VL - 23

SP - 201

EP - 204

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -